An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia

Giorgio L Colombo1, Mauro Caruggi2, Sergio Di Matteo1, Alessandro Rossi31S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Italy; 2Università degli Studi dell’Insubria, Varese, Italy; 3Università de L’Aquila, ItalyObjective: To evaluate...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Giorgio L Colombo, Mauro Caruggi, Sergio Di Matteo, Alessandro Rossi
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://doaj.org/article/fa941aaa404341eea6ececf0ad777659
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:fa941aaa404341eea6ececf0ad777659
record_format dspace
spelling oai:doaj.org-article:fa941aaa404341eea6ececf0ad7776592021-12-02T03:36:14ZAn economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia1176-63281178-2021https://doaj.org/article/fa941aaa404341eea6ececf0ad7776592008-08-01T00:00:00Zhttp://www.dovepress.com/an-economic-evaluation-of-aripiprazole-vs-olanzapine-adapted-to-the-it-a2025https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Giorgio L Colombo1, Mauro Caruggi2, Sergio Di Matteo1, Alessandro Rossi31S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Italy; 2Università degli Studi dell’Insubria, Varese, Italy; 3Università de L’Aquila, ItalyObjective: To evaluate the cost-effectiveness of aripiprazole and olanzapine in patients with schizophrenia.Methods: Data from a double-blind, randomized study demonstrating the efficacy of aripiprazole and olanzapine were used to observe new incidence of metabolic syndrome (26-week therapy) and to model the risk of developing diabetes over 5 years of therapy. Cumulative incidence of metabolic syndrome was compared using Kaplan–Meier estimates; diabetes risk was estimated using a validated, general population risk-prediction model. Economic assessment was conducted from the third-party payer perspective by evaluating pharmacotherapy costs of treating schizophrenia and medical costs associated with treating adverse metabolic effects in a hypothetical cohort of 1000 patients. Resource utilization and costs were derived from the underlying study and published data, using a 3% rate to discount costs and benefits.Results: For the patients switched from olanzapine to aripiprazole, treatment with aripiprazole was a dominant cost-saving strategy. Use of aripiprazole avoided 184 events of metabolic syndrome over 26 weeks of treatment, contributing to a real-world (RW) cost savings of €2.53 per patient and a total savings of approximately €465.52 over a 5-year period. For the same cohort, the risk-prediction model indicated that 34 occurrences of diabetes could be avoided over 5 years, corresponding to a RW cost savings of €56.86 per patient and a total saving of approximately €1,933.24. These savings reflect avoided costs in treating adverse metabolic events and comparable costs in the acquisition of aripiprazole.Conclusions: Maintenance aripiprazole therapy offers medical and economic benefits over olanzapine, reflected by reduced incidence of metabolic syndrome and diabetes and associated lower costs.Keywords: schizophrenia, cost-consequences, apripiprazole, olanzapine, metabolic syndrome, diabetes Giorgio L ColomboMauro CaruggiSergio Di MatteoAlessandro RossiDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 5, Pp 967-976 (2008)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Giorgio L Colombo
Mauro Caruggi
Sergio Di Matteo
Alessandro Rossi
An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
description Giorgio L Colombo1, Mauro Caruggi2, Sergio Di Matteo1, Alessandro Rossi31S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Italy; 2Università degli Studi dell’Insubria, Varese, Italy; 3Università de L’Aquila, ItalyObjective: To evaluate the cost-effectiveness of aripiprazole and olanzapine in patients with schizophrenia.Methods: Data from a double-blind, randomized study demonstrating the efficacy of aripiprazole and olanzapine were used to observe new incidence of metabolic syndrome (26-week therapy) and to model the risk of developing diabetes over 5 years of therapy. Cumulative incidence of metabolic syndrome was compared using Kaplan–Meier estimates; diabetes risk was estimated using a validated, general population risk-prediction model. Economic assessment was conducted from the third-party payer perspective by evaluating pharmacotherapy costs of treating schizophrenia and medical costs associated with treating adverse metabolic effects in a hypothetical cohort of 1000 patients. Resource utilization and costs were derived from the underlying study and published data, using a 3% rate to discount costs and benefits.Results: For the patients switched from olanzapine to aripiprazole, treatment with aripiprazole was a dominant cost-saving strategy. Use of aripiprazole avoided 184 events of metabolic syndrome over 26 weeks of treatment, contributing to a real-world (RW) cost savings of €2.53 per patient and a total savings of approximately €465.52 over a 5-year period. For the same cohort, the risk-prediction model indicated that 34 occurrences of diabetes could be avoided over 5 years, corresponding to a RW cost savings of €56.86 per patient and a total saving of approximately €1,933.24. These savings reflect avoided costs in treating adverse metabolic events and comparable costs in the acquisition of aripiprazole.Conclusions: Maintenance aripiprazole therapy offers medical and economic benefits over olanzapine, reflected by reduced incidence of metabolic syndrome and diabetes and associated lower costs.Keywords: schizophrenia, cost-consequences, apripiprazole, olanzapine, metabolic syndrome, diabetes
format article
author Giorgio L Colombo
Mauro Caruggi
Sergio Di Matteo
Alessandro Rossi
author_facet Giorgio L Colombo
Mauro Caruggi
Sergio Di Matteo
Alessandro Rossi
author_sort Giorgio L Colombo
title An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
title_short An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
title_full An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
title_fullStr An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
title_full_unstemmed An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
title_sort economic evaluation of aripiprazole vs olanzapine adapted to the italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/fa941aaa404341eea6ececf0ad777659
work_keys_str_mv AT giorgiolcolombo aneconomicevaluationofaripiprazolevsolanzapineadaptedtotheitaliansettingusingoutcomesofmetabolicsyndromeandriskfordiabetesinpatientswithschizophrenia
AT maurocaruggi aneconomicevaluationofaripiprazolevsolanzapineadaptedtotheitaliansettingusingoutcomesofmetabolicsyndromeandriskfordiabetesinpatientswithschizophrenia
AT sergiodimatteo aneconomicevaluationofaripiprazolevsolanzapineadaptedtotheitaliansettingusingoutcomesofmetabolicsyndromeandriskfordiabetesinpatientswithschizophrenia
AT alessandrorossi aneconomicevaluationofaripiprazolevsolanzapineadaptedtotheitaliansettingusingoutcomesofmetabolicsyndromeandriskfordiabetesinpatientswithschizophrenia
AT giorgiolcolombo economicevaluationofaripiprazolevsolanzapineadaptedtotheitaliansettingusingoutcomesofmetabolicsyndromeandriskfordiabetesinpatientswithschizophrenia
AT maurocaruggi economicevaluationofaripiprazolevsolanzapineadaptedtotheitaliansettingusingoutcomesofmetabolicsyndromeandriskfordiabetesinpatientswithschizophrenia
AT sergiodimatteo economicevaluationofaripiprazolevsolanzapineadaptedtotheitaliansettingusingoutcomesofmetabolicsyndromeandriskfordiabetesinpatientswithschizophrenia
AT alessandrorossi economicevaluationofaripiprazolevsolanzapineadaptedtotheitaliansettingusingoutcomesofmetabolicsyndromeandriskfordiabetesinpatientswithschizophrenia
_version_ 1718401709506560000